The present invention relates to a compound according to Formula (I) wherein R.sup.1 is a hydrocarbyl group selected from the group consisting of alkyl, alkenyl, aryl, aralkyl, and alkylaryl groups, and one or more combinations thereof; wherein R.sup.2 is a hydrogen atom, an aryl group or an alkyl group; and wherein R.sup.3, R.sup.4, R.sup.5 and R.sup.6, are the same or different and are each independently a hydrogen atom, a halogen atom, a cyano group, an amino group, a hydrocarbyl group selected from the group consisting of alkyl, alkenyl, aryl, aralkyl, and alkylaryl groups or an alkoxy group, and one or more combinations thereof as internal electron donor and to a process for the synthesis of a compound according to Formula (I), wherein R.sup.1 is a hydrocarbyl group selected from the group consisting of alkyl, alkenyl, aryl, aralkyl, alkoxycarbonyl and alkylaryl groups, and one or more combinations thereof; wherein R.sup.2 is a hydrogen atom or an alkyl group; wherein R.sup.3, R.sup.4, R.sup.5 and R.sup.6, are the same or different and are each independently selected from a group consisting of a hydrogen atom; a hydrocarbyl, preferably, said process comprising the step of reacting a compound according to Formula (II) [R.sup.1C(O)Cl] with a compound according to Formula (III) to obtain the compound according to Formula (I) and to the use of these compounds as internal donor in Ziegler-Natta catalysis of olefins. ##STR00001##

The present invention relates to a 5-step process for preparing iosimenol starting from ammonium 3-amino-5-(aminocarbonyl)benzoate which is first converted to 3-amino-5-(aminocarbonyl)-2,4,6-triiodobenzoic acid using sodium iodine dichloride (NaICl.sub.2). The present invention further relates to processes for purifying iosimenol.

The present invention relates to a 5-step process for preparing iosimenol starting from ammonium 3-amino-5-(aminocarbonyl)benzoate which is first converted to 3-amino-5-(aminocarbonyl)-2,4,6-triiodobenzoic acid using sodium iodine dichloride (NaICl.sub.2). The present invention further relates to processes for purifying iosimenol.

The present invention relates to a 5-step process for preparing iosimenol starting from ammonium 3-amino-5-(aminocarbonyl)benzoate which is first converted to 3-amino-5-(aminocarbonyl)-2,4,6-triiodobenzoic acid using sodium iodine dichloride (NaICl.sub.2). The present invention further relates to processes for purifying iosimenol.

The present invention relates to a new diethanolamine derivative chelating agent having a high water solubility, a good chelating property, and biological degradation. The said new chelating agent can be prepared from reaction of diethanolamine and cyclic anhydride compound using lewis acid as the catalyst. The said process is uncomplicated, and does not use a severe condition, and also reduces the use of harmful chemicals.

The present invention relates to a new diethanolamine derivative chelating agent having a high water solubility, a good chelating property, and biological degradation. The said new chelating agent can be prepared from reaction of diethanolamine and cyclic anhydride compound using lewis acid as the catalyst. The said process is uncomplicated, and does not use a severe condition, and also reduces the use of harmful chemicals.

Water-in-oil subterranean treatment fluids with improved stability and environmental compatibility comprise esteramides as emulsion stabilizer.

Water-in-oil subterranean treatment fluids with improved stability and environmental compatibility comprise esteramides as emulsion stabilizer.

The present invention relates to a fluoroallylamine derivative and use thereof. In particular, the present invention relates to a compound as shown in Formula I, a prodrug, an isomer, an isotope-labeled compound, a solvate or a pharmaceutically acceptable salt thereof, which has VAP-1/SSAO inhibitory activity, and can be used for treating a disease associated with VAP-1/SSAO overactivity.

##STR00001##

The present invention relates to a fluoroallylamine derivative and use thereof. In particular, the present invention relates to a compound as shown in Formula I, a prodrug, an isomer, an isotope-labeled compound, a solvate or a pharmaceutically acceptable salt thereof, which has VAP-1/SSAO inhibitory activity, and can be used for treating a disease associated with VAP-1/SSAO overactivity.

##STR00001##